Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026012 · ClinicalTrials.gov registry record · NA
Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT01026012 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 40 participants.
The verdict
NCT01026012, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
It is been known for at least 20 years that the hemodynamic data, the amount of exercise performed as well as symptoms on the treadmill, has significant value to the perfusion stress testing. When a pharmacologic stress test is performed (and adenosine stress test over 4-6 minutes), this hemodynamic data is lost. Because of this loss of valuable data, it is felt that there is also a loss of significant prognostic data as well. With the advent and FDA release of Regadenoson in a rapid injection form (over 10 seconds), it is thought that the combination of both exercise stress testing and pharmacologic testing in subjects that do not achieve 85% in a maximal predicted heart rate may be a viable stress testing option. The purpose of this study is to look at using the drug, regadenoson, with exercise stress testing; and the side effect symptoms that may be experienced by individual subjects using this combination.
Interventions
- DRUG regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026012
The ClinicalTrials.gov registry entry for NCT01026012 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which regadenoson is the first listed.
NCT01026012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026012 about?
NCT01026012 is a clinical study titled "Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing". It is been known for at least 20 years that the hemodynamic data, the amount of exercise performed as well as symptoms on the treadmill, has significant value to the perfusion stress testing. When a pharmacologic stress test is performed (and adenosine stress test over 4-6 minutes), this hemodynamic...
What is the current status of trial NCT01026012?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2009-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01026012?
The interventions under investigation include: regadenoson (DRUG).
Who is sponsoring clinical trial NCT01026012?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.